Cargando…
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
Coronavirus disease 2019 (COVID-19) is associated with considerable morbidity and mortality. The number of confirmed cases of infection with SARS-CoV-2, the virus causing COVID-19 continues to escalate with over 70 million confirmed cases and over 1.6 million confirmed deaths. Severe-to-critical COV...
Autores principales: | Agresti, Nicholas, Lalezari, Jacob P., Amodeo, Phillip P., Mody, Kabir, Mosher, Steven F., Seethamraju, Harish, Kelly, Scott A., Pourhassan, Nader Z., Sudduth, C. David, Bovinet, Christopher, ElSharkawi, Ahmed E., Patterson, Bruce K., Stephen, Reejis, Sacha, Jonah B., Wu, Helen L., Gross, Seth A., Dhody, Kush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823045/ https://www.ncbi.nlm.nih.gov/pubmed/33521616 http://dx.doi.org/10.1016/j.jtauto.2021.100083 |
Ejemplares similares
-
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab
por: Elneil, Sohier, et al.
Publicado: (2021) -
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species
por: Chang, Xiao L., et al.
Publicado: (2022) -
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
por: Yang, Bryant, et al.
Publicado: (2020) -
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab
por: Chang, Xiao L., et al.
Publicado: (2021) -
LERONLIMAB AND THE ROLE OF CCR5 SUPRESSION IN COVID-19 TREATMENT
por: BJORK, SARAH, et al.
Publicado: (2021)